AlloVir, Inc. (NASDAQ:ALVR) Short Interest Up 57.4% in November

AlloVir, Inc. (NASDAQ:ALVR) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 1,920,000 shares, an increase of 57.4% from the November 15th total of 1,220,000 shares. Based on an average daily trading volume, of 321,500 shares, the days-to-cover ratio is currently 6.0 days.

AlloVir Stock Performance

ALVR stock opened at $0.45 on Friday. AlloVir has a 52 week low of $0.44 and a 52 week high of $2.49. The company has a market capitalization of $52.01 million, a PE ratio of -0.51 and a beta of 0.59. The company’s 50-day simple moving average is $0.69 and its 200 day simple moving average is $0.74.

AlloVir (NASDAQ:ALVR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

Institutional Investors Weigh In On AlloVir

A number of large investors have recently added to or reduced their stakes in ALVR. Cubist Systematic Strategies LLC lifted its position in shares of AlloVir by 152.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after acquiring an additional 30,072 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of AlloVir by 127.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after purchasing an additional 54,900 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in AlloVir in the second quarter valued at about $55,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.